• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

辐射诱导肾细胞癌患者 T 细胞库的动态变化。

Radiation induces dynamic changes to the T cell repertoire in renal cell carcinoma patients.

机构信息

Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263.

Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263.

出版信息

Proc Natl Acad Sci U S A. 2020 Sep 22;117(38):23721-23729. doi: 10.1073/pnas.2001933117. Epub 2020 Sep 8.

DOI:10.1073/pnas.2001933117
PMID:32900949
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7519245/
Abstract

Clinical studies combining radiation and immunotherapy have shown promising response rates, strengthening efforts to sensitize tumors to immune-mediated attack. Thus, there is an ongoing surge in trials using preconditioning regimens with immunotherapy. Yet, due to the scarcity of resected tumors treated in situ with radiotherapy, there has been little investigation of radiation's sole contributions to local and systemic antitumor immunity in patients. Without this access, translational studies have been limited to evaluating circulating immune subsets and systemic remodeling of peripheral T cell receptor repertoires. This constraint has left gaps in how radiation impacts intratumoral responses and whether tumor-resident T cell clones are amplified following treatment. Therefore, to interrogate the immune impact of radiation on the tumor microenvironment and test the hypothesis that radiation initiates local and systemic expansion of tumor-resident clones, we analyzed renal cell carcinomas from patients treated with stereotactic body radiation therapy. Transcriptomic comparisons were evaluated by bulk RNA sequencing. T cell receptor sequencing monitored repertoires during treatment. Pathway analysis showed radiation-specific enrichment of immune-related processes, and T cell receptor sequencing revealed increased clonality in radiation-treated tumors. The frequency of identified, tumor-enriched clonotypes was tracked across serial blood samples. We observed increased abundance of tumor-enriched clonotypes at 2 wk postradiation compared with pretreatment levels; however, this expansion was not sustained, and levels contracted toward baseline by 4 wk posttreatment. Taken together, these results indicate robust intratumoral immune remodeling and a window of tumor-resident T cell expansion following radiation that may be leveraged for the rational design of combinatorial strategies.

摘要

联合放疗和免疫治疗的临床研究显示出了有希望的反应率,这加强了使肿瘤对免疫介导的攻击敏感的努力。因此,目前正在进行大量使用免疫治疗预处理方案的试验。然而,由于用放射疗法原位治疗的切除肿瘤数量稀少,因此很少研究放疗对患者局部和全身抗肿瘤免疫的单独贡献。没有这种方法,转化研究就仅限于评估循环免疫亚群和外周 T 细胞受体库的全身重塑。这种限制导致人们对放疗如何影响肿瘤内反应以及肿瘤内 T 细胞克隆在治疗后是否扩增存在空白。因此,为了探究放疗对肿瘤微环境的免疫影响,并检验放疗引发肿瘤内驻留克隆局部和全身扩增的假设,我们分析了接受立体定向体部放射治疗的肾癌患者的肿瘤样本。通过批量 RNA 测序评估转录组比较。在治疗过程中监测 T 细胞受体测序。通路分析显示辐射特异性富集免疫相关过程,T 细胞受体测序显示辐射治疗的肿瘤中克隆性增加。在一系列血液样本中跟踪鉴定出的、肿瘤富集的克隆型的频率。我们观察到与治疗前水平相比,放疗后 2 周肿瘤富集克隆型的丰度增加;然而,这种扩增没有持续下去,并且在治疗后 4 周时水平向基线收缩。综上所述,这些结果表明放疗后肿瘤内免疫重塑和肿瘤内 T 细胞扩增的窗口很大,这可能为组合策略的合理设计提供依据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d34e/7519245/8b4d8637f125/pnas.2001933117fig05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d34e/7519245/589214180160/pnas.2001933117fig01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d34e/7519245/5614533b326d/pnas.2001933117fig02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d34e/7519245/0a068514ccf2/pnas.2001933117fig03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d34e/7519245/20e3bbc35ae9/pnas.2001933117fig04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d34e/7519245/8b4d8637f125/pnas.2001933117fig05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d34e/7519245/589214180160/pnas.2001933117fig01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d34e/7519245/5614533b326d/pnas.2001933117fig02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d34e/7519245/0a068514ccf2/pnas.2001933117fig03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d34e/7519245/20e3bbc35ae9/pnas.2001933117fig04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d34e/7519245/8b4d8637f125/pnas.2001933117fig05.jpg

相似文献

1
Radiation induces dynamic changes to the T cell repertoire in renal cell carcinoma patients.辐射诱导肾细胞癌患者 T 细胞库的动态变化。
Proc Natl Acad Sci U S A. 2020 Sep 22;117(38):23721-23729. doi: 10.1073/pnas.2001933117. Epub 2020 Sep 8.
2
Tumor and immune remodeling following radiotherapy in human renal cell carcinoma.放疗后人类肾细胞癌的肿瘤和免疫重塑。
J Immunother Cancer. 2023 Apr;11(4). doi: 10.1136/jitc-2022-006392.
3
Heterogeneous expansion of CD4+ tumor-infiltrating T-lymphocytes in clear cell renal cell carcinomas.透明细胞肾细胞癌中CD4+肿瘤浸润性T淋巴细胞的异质性扩增。
Biochem Biophys Res Commun. 2015 Feb 27;458(1):70-6. doi: 10.1016/j.bbrc.2015.01.069. Epub 2015 Jan 28.
4
Role of Radiation in Treatment of Renal Cell Carcinoma.放射治疗在肾细胞癌治疗中的作用
Hematol Oncol Clin North Am. 2023 Oct;37(5):921-924. doi: 10.1016/j.hoc.2023.04.015. Epub 2023 May 26.
5
Characteristics, dynamic changes, and prognostic significance of TCR repertoire profiling in patients with renal cell carcinoma.T 细胞受体(TCR)谱分析在肾细胞癌患者中的特征、动态变化及其预后意义。
J Pathol. 2020 May;251(1):26-37. doi: 10.1002/path.5396. Epub 2020 Mar 24.
6
Genomic and Transcriptomic Predictors of Response from Stereotactic Body Radiation Therapy in Patients with Oligoprogressive Renal Cell Carcinoma.寡进展性肾细胞癌患者立体定向体部放射治疗反应的基因组和转录组预测因子。
Eur Urol Oncol. 2023 Aug;6(4):447-450. doi: 10.1016/j.euo.2022.11.006. Epub 2023 Jan 4.
7
Radiation Therapy for Patients with Advanced Renal Cell Carcinoma.晚期肾细胞癌患者的放射治疗。
Urol Clin North Am. 2020 Aug;47(3):399-411. doi: 10.1016/j.ucl.2020.04.011. Epub 2020 Jun 8.
8
Radiation therapy options in kidney cancer.肾癌的放射治疗选择。
Curr Opin Support Palliat Care. 2023 Dec 1;17(4):308-314. doi: 10.1097/SPC.0000000000000683. Epub 2023 Oct 26.
9
Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies.立体定向消融放疗治疗寡转移肾细胞癌(SABR ORCA):28 项研究的荟萃分析。
Eur Urol Oncol. 2019 Sep;2(5):515-523. doi: 10.1016/j.euo.2019.05.007. Epub 2019 Jul 11.
10
When Surgery Is Not an Option in Renal Cell Carcinoma: The Evolving Role of Stereotactic Body Radiation Therapy.当手术不是肾细胞癌的选择时:立体定向体部放射治疗的不断发展的作用。
Oncology (Williston Park). 2019 May 14;33(5):167-73, 177.

引用本文的文献

1
Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma.全面的肿瘤免疫分析揭示了肉瘤样肾细胞癌中矛盾免疫敏感性的介质。
Cancer Cell. 2025 Jul 23. doi: 10.1016/j.ccell.2025.07.010.
2
Impact of stereotactic radiosurgery timing relative to immune checkpoint blockade administration on brain metastasis disease and radionecrosis outcomes.立体定向放射外科治疗时机相对于免疫检查点阻断剂给药对脑转移瘤疾病和放射性坏死结局的影响。
Neurooncol Adv. 2025 Jun 18;7(1):vdaf130. doi: 10.1093/noajnl/vdaf130. eCollection 2025 Jan-Dec.
3
A feasibility trial of delayed resection for brain metastases following pre-operative stereotactic radiosurgery.

本文引用的文献

1
Measuring Intratumoral Heterogeneity of Immune Repertoires.测量免疫组库的肿瘤内异质性。
Front Oncol. 2020 May 8;10:512. doi: 10.3389/fonc.2020.00512. eCollection 2020.
2
Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy.免疫疗法一个周期后外周 T 细胞动力学揭示的免疫唤醒。
Nat Cancer. 2020 Feb;1(2):210-221. doi: 10.1038/s43018-019-0022-x. Epub 2020 Feb 10.
3
An intra-tumoral niche maintains and differentiates stem-like CD8 T cells.肿瘤内龛位维持并分化具有干细胞样特征的 CD8+T 细胞。
术前立体定向放射治疗后延迟切除脑转移瘤的可行性试验。
J Neurooncol. 2025 May 26. doi: 10.1007/s11060-025-05081-2.
4
Advances in cancer immunotherapy: historical perspectives, current developments, and future directions.癌症免疫疗法的进展:历史回顾、当前发展及未来方向。
Mol Cancer. 2025 May 7;24(1):136. doi: 10.1186/s12943-025-02305-x.
5
Radical hemithorax radiotherapy induces an increase in circulating PD-1 T lymphocytes and in the soluble levels of PD-L1 in malignant pleural mesothelioma patients: a possible synergy with PD-1/PD-L1 targeting treatment?根治性半胸放疗可使恶性胸膜间皮瘤患者循环中的PD-1 T淋巴细胞及PD-L1可溶性水平升高:这是否与PD-1/PD-L1靶向治疗存在协同作用?
Front Immunol. 2025 Apr 1;16:1534766. doi: 10.3389/fimmu.2025.1534766. eCollection 2025.
6
Pre-immunotherapy alters stereotactic ablative radiotherapy-induced systemic T cell responses in early-stage NSCLC.免疫治疗前改变早期非小细胞肺癌中立体定向消融放疗诱导的全身T细胞反应。
Cancer Immunol Immunother. 2025 Feb 1;74(3):80. doi: 10.1007/s00262-024-03935-8.
7
Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma.局限性、复发性和转移性肾细胞癌的原发部位立体定向消融体部放疗
Clin Transl Radiat Oncol. 2024 Oct 28;49:100879. doi: 10.1016/j.ctro.2024.100879. eCollection 2024 Nov.
8
Integrating IL-12 mRNA nanotechnology with SBRT eliminates T cell exhaustion in preclinical models of pancreatic cancer.将白细胞介素-12信使核糖核酸纳米技术与立体定向体部放疗相结合,可消除胰腺癌临床前模型中的T细胞耗竭。
Mol Ther Nucleic Acids. 2024 Sep 30;35(4):102350. doi: 10.1016/j.omtn.2024.102350. eCollection 2024 Dec 10.
9
Stereotactic Body Radiotherapy for Renal Cell Carcinoma-A Review of Use in the Primary, Cytoreductive and Oligometastatic Settings.立体定向体部放射治疗在肾癌中的应用——原发性、减瘤性和寡转移性治疗情况综述
Cancers (Basel). 2024 Sep 29;16(19):3334. doi: 10.3390/cancers16193334.
10
Quantifiable TCR repertoire changes in prediagnostic blood specimens among patients with high-grade ovarian cancer.高级别卵巢癌患者诊断前血液样本中可量化的T细胞受体库变化。
Cell Rep Med. 2024 Jul 16;5(7):101612. doi: 10.1016/j.xcrm.2024.101612. Epub 2024 Jun 14.
Nature. 2019 Dec;576(7787):465-470. doi: 10.1038/s41586-019-1836-5. Epub 2019 Dec 11.
4
The reactome pathway knowledgebase.Reactome 通路知识库。
Nucleic Acids Res. 2020 Jan 8;48(D1):D498-D503. doi: 10.1093/nar/gkz1031.
5
Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre study.立体定向体部放射治疗联合全身治疗转移性肾细胞癌:一项前瞻性多中心研究。
ESMO Open. 2019 Oct 13;4(5):e000535. doi: 10.1136/esmoopen-2019-000535. eCollection 2019.
6
Survival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors.立体定向体部放疗联合酪氨酸激酶抑制剂治疗转移性肾细胞癌患者的生存结局。
Am J Clin Oncol. 2020 Jan;43(1):58-63. doi: 10.1097/COC.0000000000000622.
7
Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer.立体定向消融放疗(SAbR)用于延缓寡转移肾细胞癌的全身治疗。
Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):367-375. doi: 10.1016/j.ijrobp.2019.07.023. Epub 2019 Aug 1.
8
Clonal replacement of tumor-specific T cells following PD-1 blockade.PD-1 阻断后肿瘤特异性 T 细胞的克隆性替换。
Nat Med. 2019 Aug;25(8):1251-1259. doi: 10.1038/s41591-019-0522-3. Epub 2019 Jul 29.
9
The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.立体定向消融放疗治疗原发性肾细胞癌的新作用:系统评价和荟萃分析。
Eur Urol Focus. 2019 Nov;5(6):958-969. doi: 10.1016/j.euf.2019.06.002. Epub 2019 Jun 24.
10
Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial.转移性三阴性乳腺癌的免疫诱导策略,以提高对 PD-1 阻断的敏感性:TONIC 试验。
Nat Med. 2019 Jun;25(6):920-928. doi: 10.1038/s41591-019-0432-4. Epub 2019 May 13.